Leading the Way in Life Science Technologies

GEN Exclusives

More »

Sidebars

More »
Jan 15, 2009 (Vol. 29, No. 2)

BD Biosciences Expands Capabilities in Cell Culture Media

  • While BD Biosciences works toward completing construction of its recently announced animal-free/antibiotic-free (AF2) cell culture media production facility in Miami by the end of the year, the company’s new pilot lab is nearing completion.

    The pilot plant will focus on the production of cell culture media samples representative of the new commercial-scale AF2 facility, according to company officials. Custom blends of basal cell culture media and supplements are available currently via the BD Autonutrient™ media design service and its custom product development program, they add.

    Once the Miami facility begins operations, “BD Biosciences will fully serve the culture media needs of bioprocessors working with mammalian, microbial, or stem cell lines,” notes Tom Isett, vp, BD Biosciences–Advanced Bioprocessing.

    Originally designed and built for the manufacture of pharmaceuticals, the 90,000-square foot Miami plant is currently being outfitted with modern cell culture media milling, blending, and sterile liquid filling equipment.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »